

March 13, 2025

This past week, Brain Tumour Foundation of Canada's advocacy and information specialist met with a representative from Health Canada's Drug Shortages Unit to discuss the pending discontinuation of lomustine.

Health Canada has confirmed that there is adequate supply of lomustine to meet the needs of Canadian patients for several more months. Health Canada is working closely with stakeholders and has prioritized securing additional supply.

BTFC is actively navigating the discontinuation and continues to have frequent communication with Health Canada regarding progress towards a solution.

To learn more about Brain Tumour Foundation of Canada's efforts regarding the lomustine discontinuation, please [visit this page](#).

If you have any questions or concerns about this issue or Brain Tumour Foundation of Canada's advocacy efforts, please contact:

Sarah Rogers

Advocacy and information specialist [srogers@braintumour.ca](mailto:srogers@braintumour.ca)